This protocol addresses leukemia cutis occurring in the specific setting of chronic myelomonocytic leukemia (CMML) — a presentation that reflects systemic disease involvement of the skin and shapes the treatment strategy accordingly.
Chronic myelomonocytic leukemia (CMML) is a hematological malignancy that shares features of both myelodysplastic syndrome and myeloproliferative neoplasms, with an estimated incidence of approximately four cases per 100,000 persons per year. The development of leukemia cutis in this context indicates cutaneous spread of the underlying hematologic disease and directly informs the systemic management approach.
Management in this setting is systemic and directed at the underlying CMML. The protocol involves cytoreductive or hypomethylating strategies, with agent selection guided by specific clinical criteria.
DOI: 10.3390/cancers15225393
Chronic myelomonocytic leukemia (CMML) is a hematological malignancy with the characteristics of myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs), of which incidence has been found to be approximately four cases per 100,000 persons per year.
Cytoreductive therapy with hydroxyurea or other cytotoxic drugs is indicated in most patients.
Treatment with hypomethylating agents such as 5-azacitidine and decitabine can yield overall response rates of 30-40% and complete response rates of 7% to 17%.
View source ↗